Evidence map›Paper›PMID 35896520›Full record

ArticleCell death & disease2022

ARHGEF2/EDN1 pathway participates in ER stress-related drug resistance of hepatocellular carcinoma by promoting angiogenesis and malignant proliferation.

Yue Zhu, Weiwei Liu, Zishu Wang, Yanfei Wang, Chaisheng Tan, Zhipeng Pan, Anqi Wang, Jiatao Liu, Guoping Sun

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yue Zhu *Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Weiwei Liu *Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Zishu Wang *Department of Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.ORCID 0000-0002-1625-2195
Yanfei WangDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Chaisheng TanDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Zhipeng PanDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Anqi WangDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Jiatao LiuDepartment of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Guoping SunDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. sungp@ahmu.edu.cn.ORCID 0000-0002-4325-900X
Anhui Medical University · CNFirst Affiliated Hospital of Bengbu Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endoplasmic reticulum (ER) stress is widely involved in the drug resistance of hepatocellular carcinoma (HCC), but the mechanism of ER stress-induced drug resistance involves multiple signaling pathways that cannot be fully explained. Exploring genes associated with ER stress could yield a novel therapeutic target for ER stress-induced drug resistance. By analyzing RNA-sequencing, ATAC-sequencing, and Chip-sequencing data of Tunicamycin (TM)-treated or untreated HCC cells, we found that Rho guanine nucleotide exchange factor 2 (ARHGEF2) is upregulated in HCC cells with ER stress. ARHGEF2 plays an active role in tumor malignant progression. Notwithstanding, no research has been done on the link between ER stress and ARHGEF2. The function of ARHGEF2 as a novel downstream effector of ER stress in the angiogenesis and treatment resistance of HCC was revealed in this work. ARHGEF2 overexpression was linked to malignant development and a poor prognosis in HCC. ER stress stimulates the expression of ARHGEF2 through upregulation of ZNF263. Elevated ARHGEF2 accelerates HCC angiogenesis via the EDN1 pathway, enhances HCC cell proliferation and tumor growth both in vitro and in vivo, and contributes to ER stress-related treatment resistance. HCC cell growth was more inhibited when ARHGEF2 knockdown was paired with targeted medicines. Collectively, we uncovered a previously hidden mechanism where ARHGEF2/EDN1 pathway promotes angiogenesis and participates in ER stress-related drug resistance in HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsCell Line, TumorCell ProliferationDrug ResistanceEndoplasmic Reticulum StressHumansNeovascularization, PathologicRho Guanine Nucleotide Exchange FactorsARHGEF2 protein, humanRho Guanine Nucleotide Exchange Factors

Identifiers

PMID35896520
PMCPMC9329363
OpenAlexW4288056763

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.